Biogen’s aducanumab stumbles on cognitive endpoints at 6 mg/kg dose

WASHINGTON – An antiamyloid antibody that showed significant cognitive benefit at 10 mg/kg failed to deliver similar good news at a lower dose in the first randomized, antiamyloid antibody trial...